Skip to content

ASLAN Pharmaceuticals Limited

CIK 0001722926

← back to feed
Revenue (TTM)
—
FY Dec 2023
Net Income (TTM)
−$44.22M
+13.9% YoY FY Dec 2023
EPS Diluted (TTM)
−$0.11
+26.7% YoY FY Dec 2023
Gross Margin
—
FY Dec 2023
Operating Margin
—
FY Dec 2023
Net Margin
—
FY Dec 2023
Free Cash Flow (TTM)
—
FY Dec 2023
Cash
$21.25M
FY Dec 2023
Total Debt
—
FY Dec 2023
Shares Outstanding
402.12M sh
FY Dec 2023

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings